Fig. 6: Distribution of del(5q) cells within CD34+ progenitors after lenalidomide treatment. | Nature Communications

Fig. 6: Distribution of del(5q) cells within CD34+ progenitors after lenalidomide treatment.

From: Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

Fig. 6

A UMAP depicting the del(5q) density across the different hematopoietic progenitors obtained in three patients after lenalidomide treatment. HSC hematopoietic stem cells, LMPP lymphoid-primed multipotent progenitors, GMP granulocyte-monocyte progenitors; granulocyte progenitors; monocyte progenitors; dendritic cell progenitors, CLP common lymphoid progenitors; B-cell progenitors; T-cell progenitors, MEP megakaryocyte-erythroid progenitors, MK_Prog megakaryocyte progenitors; early erythroid progenitors; late erythroid progenitors; basophil progenitors. B Barplots showing the number of del(5q) and non-del(5q) cells composing each cell type for each MDS patient. C Percentage of the cells identified as del(5q) by karyotype, CASPER, CopyKat, and the selection by intersecting the two algorithms. D Heatmap representing the enrichment of del(5q) cells (log10(p-value)) in each cell type. Any color different from white represents a statistically significant enrichment of del(5q) cells (p-value < 0.05). P-values were calculated using the one-sided hypergeometric test. The number of biologically independent replicates (cells) used for the hypergeometric test and the exact enrichment p-values can be found in the Source Data.

Back to article page